Kodu・Aktsiate loetelu・Sana Biotechnology Inc

Sana Biotechnology Inc

Suletud

SektorTervishoid

3.79 5.28

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

3.5300000000000002

Max

3.8

Põhinäitajad
By Trading Economics
Sissetulek	-16M -64M
Aktsiakasum	-0.13
Töötajad	142
EBITDA	-21M -65M

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+128.53% upside

Dividendid
By Acuity
Järgmine tulemuste avaldamine	14. aug 2026

Turustatistika
By TradingEconomics
Turukapital	120M 1B
Eelmine avamishind	-1.49
Eelmine sulgemishind	3.79

Uudiste sentiment

By Acuity

25%

75%

49 / 340 Pingereas Healthcare

Sana Biotechnology Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

11. aug 2026, 19:31 UTC

News

Sana Biotechnology shares are higher following Q2 results showing an adjusted EPS of -$0.13, exceeding estimates, and a $25 million investment from Mayo Clinic.

10. aug 2026, 23:01 UTC

News

Sana Biotechnology Inc shares are lower in after-market hours following a second-quarter loss of $63.6 million, despite an adjusted EPS that exceeded expectations.

7. aug 2026, 19:56 UTC

Sana Biotechnology Inc. shares are higher, supported by broader market dynamics following a disappointing jobs report easing interest rate concerns.

5. aug 2026, 19:56 UTC

Sana Biotechnology Inc. is trading higher during Wednesday's session, having peaked earlier before pulling back slightly while remaining above its 20-day moving average.

4. aug 2026, 20:05 UTC

Sana Biotechnology Inc shares are higher, reflecting strong performance amid a decline in crude oil prices, which may ease inflationary pressures.

3. aug 2026, 19:46 UTC

Sana Biotechnology Inc is higher today, benefiting from a broader market rally, particularly in technology, despite earlier session pullbacks.

31. juuli 2026, 23:06 UTC

Sana Biotechnology Inc shares are lower in after-market hours, retracing from earlier gains. Broader market trends show mixed sentiment among major tech firms.

30. juuli 2026, 19:29 UTC

Sana Biotechnology Inc shares are higher today, recovering from earlier lows. The stock has shown an upward trend since Wednesday's close.

29. juuli 2026, 23:36 UTC

Sana Biotechnology Inc shares are higher in after-market hours, reflecting a slight increase since Wednesday's close amid routine market activity and broader volatility.

28. juuli 2026, 18:03 UTC

Sana Biotechnology Inc. shares are higher as biotechnology stocks advance, though they diverge from a recent trend of daily gains since Monday's close.

27. juuli 2026, 19:07 UTC

Sana Biotechnology Inc shares are higher today, continuing a rally since Friday. No specific news has been identified to explain the price movement.

24. juuli 2026, 18:26 UTC

Sana Biotechnology Inc. shares are trading lower amid broader market volatility, with no specific company news identified to explain the decline.

22. juuli 2026, 19:36 UTC

News

Sana Biotechnology has shifted focus to B-cell autoimmune disorders amid competition in oncology. Shares are higher since Tuesday, supported by rising crude oil prices.

20. juuli 2026, 17:56 UTC

Social Media

Sana Biotechnology Inc shares are lower, continuing a nine-session decline. Social media discussions raise skepticism about the timeline for its allogeneic cell therapies.

Võrdlus sarnastega

Hinnamuutus

Sana Biotechnology Inc Prognoos

Hinnasiht

By TipRanks

128.53% tõus

12 kuu keskmine prognoos

Keskmine 8.25 USD 128.53%

Kõrge 12 USD

Madal 7 USD

Põhineb 4 Wall Streeti analüütiku instrumendi Sana Biotechnology Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

4 ratings

Osta

Hoia

Müü

Põhineb 4 analüütiku instrumendi Sana Biotechnology Inc aktsia reitingul - viimase 3 kuu andmed.

Sentiment

By Acuity

49 / 340 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Sana Biotechnology Inc

Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others. The company's product candidates include SC291 that is used as allogeneic cell therapies for hematologic malignancies; ARDENT for a potential treatment for non-Hodgkin's lymphoma, and chronic lymphoblastic leukemia; GLEAM, to treat multiple autoimmune disorders that involve production of autoimmune antibodies, including lupus nephritis, extrarenal lupus, antineutrophil cytoplasmic antibody -associated vasculitis, and others. It is developing SC262 to treat patients with relapsed and/or refractory B-cell malignancies; SC255 for multiple myeloma treatment; SC379, a therapy for patients with certain central nervous system disorders healthy allogeneic glial progenitor cells; SC451, a product candidate to treat diabetes, with an initial focus on type 1 diabetes mellitus; and UP421 that reduces long-term exogenous insulin dependence. The company has an option and license agreement with Beam Therapeutics Inc. for use of Beam's proprietary CRISPR Cas12b nuclease editing technology to research, develop, and commercialize engineered cell therapy products; and a license agreement with Harvard College to access certain intellectual property for the development of hypoimmune-modified cells. The company was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. Sana Biotechnology, Inc. was incorporated in 2018 and is headquartered in Seattle, Washington.